Stocks - r/Stocks Daily Discussion Monday - Apr 05, 2021 |
- r/Stocks Daily Discussion Monday - Apr 05, 2021
- Microsoft wins U.S. Army contract for augmented reality headsets, worth up to $21.9 billion over 10 years
- Breaking: GameStop Announces At-The-Market Equity Offering Program
- Janet Yellen to call for global minimum tax rate
- Anyone holding Petco (WOOF)? It’s being shorted over %26 for some reason. I like the potential.
- $GLSI DD for Greenwich LifeSciences huge catalyst 04/09 premarket
- U.S. Market Recap - Monday, April 5, 2021
- Dow, S&P 500 rally to records, boosted by strong economic data
- Stock Simulator Apps for kids?
- DraftKings Acquires BlueRibbon
- Here is a Market Recap for today Monday, April 5, 2021
- Stock vs leap option
- What’s up with Viacom-CBS?
- Best stocks for Biden's infrastructure plan
- I just made my first call option trade.
- Heron Therapeutics [HRTX] biotech //
- Is The U.S. Finally Embracing Tidal Energy?
- TDOC: Polarizing Analyst Ratings
- Parking some money in EPD for a year for the dividend? Good idea?
- NNOX receives FDA clearance
- Resources to learn about ad tech business
- Can someone help me understand how the Coca Cola Company is set up?
- Reasons to be Bullish about Novavax (NVAX)
- What are the alternatives to VOO and VTI for european investors?
- My attempt at a 50K portfolio allocation
| r/Stocks Daily Discussion Monday - Apr 05, 2021 Posted: 05 Apr 2021 02:30 AM PDT These daily discussions run from Monday to Friday including during our themed posts. Some helpful links:
If you have a basic question, for example "what is EPS," then google "investopedia EPS" and click the investopedia article on it; do this for everything until you have a more in depth question or just want to share what you learned. Please discuss your portfolios in the Rate My Portfolio sticky.. See our past daily discussions here. Also links for: Technicals Tuesday, Options Trading Thursday, and Fundamentals Friday. [link] [comments]  |
| Posted: 04 Apr 2021 06:08 PM PDT The U.S. Army said Wednesday that Microsoft has won a contract to build more than custom HoloLens augmented reality headsets. The contract for over 120,000 headsets could be worth up to $21.88 billion over 10 years, a Microsoft spokesperson told CNBC. The deal shows Microsoft can generate meaningful revenue from a futuristic product resulting from years of research, beyond core areas such as operating systems and productivity software. It follows a $480 million contract Microsoft received to give the Army prototypes of the Integrated Visual Augmented System, or IVAS, in 2018. The new deal will involve providing production versions. The standard-issue HoloLens, which costs $3,500, enables people to see holograms overlaid over their actual environments and interact using hand and voice gestures. An IVAS prototype that a CNBC reporter tried out in 2019 displayed a map and a compass and had thermal imaging to reveal people in the dark. The system could also show the aim for a weapon. "The IVAS headset, based on HoloLens and augmented by Microsoft Azure cloud services, delivers a platform that will keep soldiers safer and make them more effective," Alex Kipman, a technical fellow at Microsoft and the person who introduced the HoloLens in 2015, wrote in a blog post. "The program delivers enhanced situational awareness, enabling information sharing and decision-making in a variety of scenarios." The headset enables soldiers to fight, rehearse and train in one system, the Army said in a statement. The contract, which was awarded on Friday, has a five-year base period, with a five-year option after that, an Army spokesperson told CNBC an email. The Pentagon did not immediately respond to a request for comment. The deal makes Microsoft a more prominent technology supplier to the U.S. military. In 2019, Microsoft secured a contract to provide cloud services to the Defense Department, beating out Amazon, the leader of the public-cloud market. Amazon has been challenging the contract, which could be worth up to $10 billion, in federal court. [link] [comments]  |
| Breaking: GameStop Announces At-The-Market Equity Offering Program Posted: 05 Apr 2021 04:35 AM PDT GameStop Corp. fell early on Monday after the company said it may sell up to $1 billion worth of additional shares in an at-the-market equity offering program. Company Can Sell Up to 3.5 Million Shares and Intends to Use Any Proceeds to Further Accelerate Transformation and Strengthen Balance Sheet. (Proceeds will not exceed 1 billion). Gamestop investor relations: https://investor.gamestop.com/news-releases/news-release-details/gamestop-announces-market-equity-offering-program [link] [comments]  |
| Janet Yellen to call for global minimum tax rate Posted: 05 Apr 2021 04:17 AM PDT Janet Yellen will use her first major address as Treasury secretary to argue for a global minimum corporate tax rate, Axios has learned, as she makes the case for President Biden's plan to raise U.S. corporate taxes to fund his $2 trillion+ infrastructure plan. Why it matters: Convincing other countries to impose a global minimum tax would reduce the likelihood of companies relocating offshore, as Biden seeks to increase the corporate rate from 21% to 28%. "Competitiveness is about more than how U.S.-headquartered companies fare against other companies in global merger and acquisition bids," Yellen will say today in a speech to the Chicago Council on Global Affairs, according to an excerpt of her prepared remarks obtained by Axios. "It is about making sure that governments have stable tax systems that raise sufficient revenue to invest in essential public goods and respond to crises, and that all citizens fairly share the burden of financing government." "We are working with G20 nations to agree to a global minimum corporate tax rate that can stop the race to the bottom." The big picture: President Trump lowered the U.S. rate from 35% to 21%, arguing that U.S. companies were at a global disadvantage and were being incentivized to relocate offshore. The average corporate rate in the G7 is 24%, with some nine countries recently lowering their corporate rate, according to the Tax Foundation, a conservative tax group. Biden's plan would also raise the international minimum rate for foreign profits from U.S. companies from 10.5% to 21%, which would still be lower than the 28% domestic corporate rate. Driving the news: Biden has tapped five Cabinet secretaries to explain — and sell — his plan to the American public, including Transportation Secretary Pete Buttigieg, Energy Secretary Jennifer Granholm, Housing and Urban Development Secretary Marcia Fudge, Labor Secretary Marty Walsh and Commerce Secretary Gina Raimondo. Yellen's task is to make the international case. Her speech also is designed to set the tone for the annual spring International Monetary Fund and World Bank meetings in Washington, which will begin virtually this week. Between the lines: Biden has been relying on Yellen to convince the business community and reassure Wall Street that his $2 trillion+ infrastructure proposal, on top of his $1.9 trillion stimulus package, won't lead to inflation. Now he's deploying her to convince international finance ministers and central bankers that the world's biggest economies need to act in concert on corporate rates to avoid a race to the bottom. Go deeper: Yellen will also challenge the world's economic powers to focus on climate change and on ways to improve vaccine access for the world's poorest countries. She will call for $650 billion in new "Special Drawing Rights" — essentially lines of credit at the IMF that can help developing countries access more U.S. dollars. The Trump administration was skeptical of new SDR allocations and many congressional Republicans are still opposed. The bottom line: By trying to convince other countries to impose a global minimum tax, Yellen is acknowledging the risks to the American economy if it acts alone in raising corporate rates. "Together we can use a global minimum tax to make sure the global economy thrives based on a more level playing field in the taxation of multinational corporations, and spurs innovation, growth, and prosperity," she will say. Source : https://www.axios.com/janet-yellen-global-minimum-tax-rate-51c7395b-e46a-4a5c-b18b-bdcf5d8bd352.html [link] [comments]  |
| Anyone holding Petco (WOOF)? It’s being shorted over %26 for some reason. I like the potential. Posted: 05 Apr 2021 12:03 PM PDT Petco has recently implemented some changes to their business model and just recently cut out raw hides from their stores. I like where they are going with the company. It's trading very low at the moment and with their online business really picking up momentum I think Petco is going places in the foreseen future. [link] [comments]  |
| $GLSI DD for Greenwich LifeSciences huge catalyst 04/09 premarket Posted: 05 Apr 2021 08:04 AM PDT I'm not sure why reddit is sleeping on GLSI this week. This stock has shown what it can do, has already started running up, and i dont see any real posts of substance on here so I figured after the run up it had this morning that there would be a couple of curious traders coming on here to learn more. I hope this helps. Extremely long DD for the Pros! Extra rocketships for the bros! 🚀 The following is taken from my own personal DD so the format is not phenomenal (for instance, cant use any pictures) so just hmu if you want the complete DD in a Greenwich LifeScience $GLSI Personal DD for entertainment purposes only. This is not financial advice. Always conduct your own DD before opening any positions. About $GLSI Greenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, that is developing GP2, a novel peptide immunotherapy, and is planning to commence a Phase III clinical trial (https://greenwichlifesciences.com). GP2 is derived from the HER2/neu protein, which is expressed in a variety of common cancers, including breast cancer. Tumors with elevated expression of HER2/neu protein are highly aggressive, resulting in an increased disease recurrence and a worse prognosis. In a Phase IIb clinical trial in the HER2/neu 3+ adjuvant setting, no breast cancer recurrences were observed after median 5 years of follow-up if the patient was fully immunized. In addition, GP2 treatment is well tolerated and no serious adverse events related to GP2 immunotherapy were reported. Upcoming Potential Catalysts for 2021 April 9-10- Greenwich is to announces more GP2 data on at the AACR (American Association for Cancer Research) annual meeting, where the company will release the final 5-year immune response results from its Phase IIb trial (https://investor.greenwichlifesciences.com/news-events/ir-calendar/detail/7476/american-association-for-cancer-research-aacr-annual). The AACR plans to publish two Greenwich LifeSciences abstracts on April 9, 2021 at 12:01 am EST and posters on April 10, 2021 on its Phase IIb clinical trial's final five year immune response data and its planned Phase III clinical trial updated design. Obviously I can't predict the future, but I hypothesize- determinate on the outcome of the results- that price action will be fire in the premarket and could start as early as 04:00:01 est. For that reason I am planning to set a GTC, extended hours, limit order the night before (04/08) with a lofty price target as things can get crazy in the premarket with low volume and high volatility. Planned Phase III Trial: 9 amino acid HER2/neu peptide + GM-CSF immunotherapy for breast cancer in adjuvant/neoadjuvant setting (postsurgery) in HER2/neu 3+, HLA-A2 patients in Y2 following Herceptin or Kadcyla. You can see the clinical trial design here: https://greenwichlifesciences.com/wp-content/uploads/2020/12/GLSI-SABCS-2020-GP2-Phase-III-OT-13-03-Poster.pdf 1 Year Price History $GLSI IPO'd closed September 29th, 2020. The 180 day lock up period ended on March 24th, so one doesn't need to worry about that. Breast Cancer I'm not going to go into an overview of what breast cancer is, if you want to know more->https://lmgtfy.app/?q=what+is+breast+cancer%3F. But here are some easily digestible facts to illustrate it's likelihood, frequency, and most importantly the unmet need for improved treatment One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018, all of whom have the potential to experience breast cancer recurrences (Source: American Cancer Society). HER2/neu 3+ ("HER2-positive") breast cancer patients comprise approximately 25% of all breast cancer patients (Source: American Society of Clinical Oncology). For women in the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer. Breast cancer is the most commonly diagnosed cancer among American women. In 2021, it's estimated that about 30% of newly diagnosed cancers in women will be breast cancers. Breast cancer became the most common cancer globally as of 2021, accounting for 12% of all new annual cancer cases worldwide, according to the World Health Organization. About 85% of breast cancers occur in women who have no family history of breast cancer. These occur due to genetic mutations that happen as a result of the aging process and life in general, rather than inherited mutations. The most significant risk factors for breast cancer are sex (being a woman) and age (growing older). This is significant because these are not factors one can necessarily change, as opposed to being able to reduce your risk for lung cancer by not smoking, avoiding radiation, and radon, etc. https://www.breastcancer.org/symptoms/understand_bc/statistics Unmet Need So what does that mean? $GLSI isn't trying to replace current therapies, but work in tangent with them and is designed to be compatible with future derivatives: So the way I see this, GLSI isn't trying to come into the marketplace as a competitor to the current treatment options available (which would be a much harder pitch to doctors who are currently using Herceptin, Kadcyla, or Enhertu) but as a supplementary treatment. "GP2 & GM-CSF starting in Year 2 act synergistically with Herceptin to prevent cancer recurrences, if fully immunized, reducing recurrence rates from 11% to 0% at median 5 years follow-up (p = 0.0338), with minimal to no side effects & no SAEs." "In the initial GP2 indication, approximately 17,000 new patients could be treated per year, saving up to 1,500 to 2,000 lives per year." (pg4) Side note: notice that the quote above didn't really need to be said; and definitely not included in a presentation of clinical data (presumably every doctor scrutinizing the results can do simple math). As an investor, this is one of the many things that make me very bullish about GLSI. A company could get fantastic clinical results but as the average investor doesn't know how to interpret the results, if the company doesn't present them in an easily digestible form, many investors will (rightfully so) pass on trading that position. And GLSI does that. You don't even need a GED to open their PR, see "0% recurrence of breast cancer in 96 patients over 5 years" and "results indicate GP2 could save up to 1,500 to 2,000 lives per year" to know that is great news and hop in a position trading on that news. More people trading => more volume, and on a low float stock like GLSI (2.69M shares according to yahfin) it will not take much to get the share price moving. If GLSI comes out and shows that the rest of their data is as good as their top-line, it will be a very profitable day for trading. Instead of cancer, imagine GLSI was focusing on migraines and their medicine gets FDA approved. Now why would the doctor prescribe GLSI over some other company that he has been prescribing for years and years he knows works fairly well (so harder to get into the marketplace = less sales = less revenue)? Not to mention the doctor's probably got connections and fiscal incentives already connected to the current treatment options, so again there would be less incentive to prescribe GLSI. But what if you went to the doctor's with a migraine, got treated for your migraine using your doctor's preferred treatment options (so he's still happy) and then as a patient was provided with an option to take a booster pill. The doctor tells you, so far about 100 people have taken the booster pill and NONE of them have had ANY migraines in the 5 years since taking it. On top of that, there have been little to NO side effects after taking the booster pill. So would you take the booster pill to safely and effectively eliminate the possibilities of a migraine every coming back (or at least, for the next 5+ years)? Now replace migraine with breast cancer, and that booster pill is $GLSI Breast cancer (ALL cancer) is extremely scary, I don't even pretend to know what kind of impact that diagnosis can have on one's life. I am apart of a family who has been horribly affected by cancer and I know we would do anything to prevent having to relive that experience nightmare. And as breast cancer is the number 1 common cancer globally, I know my family is not alone in this feeling of desperation. ELI5: Additional Details 4 clinical trials. 138 treated breast cancer patients. No cancer recurrences if fully immunized. No reported serious adverse events. Well tolerated safety profile. Thus far, the safety and efficacy of the GP2 immunotherapy have been tested in four clinical trials, where 138 patients have received treatment to date. The past trials consist of three Phase I clinical trials and one Phase IIb clinical trial. In a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) Phase IIb clinical trial led by MD Anderson and completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up if the patient was fully immunized with GP2 (p = 0.0338). Full immunization was received in the Primary Immunization Series (PIS), which included the first 6 GP2 + GM-CSF intradermal injections over the first 6 months. The PIS elicited a potent immune response as measured by local skin tests and immunological assays. Further, booster injections given every 6 months prolonged the immune response, thereby providing longer term protection. In the Phase IIb and three Phase I clinical trials, there were no reported serious adverse events related to the GP2 immunotherapy. 89 patients treated with GP2 + GM-CSF, 91 placebo patients treated with GM-CSF 17 patients treated with GP2 + GM-CSF + trastuzumab 14 patients treated with GP2 + AE37 + GM-CSF 18 patients treated with GP2 + GM-CSF Top performing IPO in 2020 (https://www.nasdaq.com/articles/this-was-the-top-performing-ipo-in-2020-2020-12-28). On December 8, 2020, GLSI share price closed at $5.20 per share. Then GLSI published its 5-year breast cancer data from a Phase IIb trial on December 9, which showed 0% breast cancer recurrences over 5 years of follow-up. On that day, the company's stock spiked to $158 per share and closed at $57 per share, surging the next day to $128 per share and closing at $72 per share. This shows huge (positive) market sentiment towards the data and it is reasonable to assume the market will react similarly on similar news. Perhaps even stronger since this data set will be the complete results. The company experienced another spike in share price on March 8, 2021, opening at $23 per share, spiking at $53 per share, before finally closing at $37 per share when it was announced that Dr. Jaye Thompson would be brought on full time to lead the GP2 Phase III trial in the fight against breast cancer. A 130% increase in share price just on the news of HIRING someone for phase III shows the market is still very much interested in Greenwich's GP2 trial. Market Sentiment Insider Information CEO Snehal Patel with 30 years of experience working in biopharma and Wall Street, Dr. Thompson has 30 years of experience managing over 200 clinical trials, CMO Joe Daugherty, who has assisted over 20 public and private biopharma companies, and Chairman David McWilliams, who on top of 45 years of experience has served as CEO of 2 private and 3 public biotech companies. The management team also owns the majority of the shares of Greenwich. Shares Outstanding: 12,846,897 shares Insider Shares: 15,863,075 shares Insider Ownership: 123.48% Insider Ownership (Float): 623.28% Total Insiders : 8 Total Directors: 5 Total Officers: 3 As of 04/04/2021 https://www.benzinga.com/general/biotech/21/03/20282424/greenwich-lifesciences-could-see-another-spike-in-stock-in-early-april, https://fintel.io/n/us/glsi Additional Clinical Trials (all completed) Protocol No. C.2007.098/IRBNet# 363083 • Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ Node-Positive and High-Risk Node-Negative Breast Cancer Patients to Prevent Recurrence. • 89 patients treated with GP2 + GM-CSF, 91 placebo patients treated with GM-CSF Protocol No. C.2008.146/ IRBNet# 363196 • Phase Ib Trial of Combination Immunotherapy with HER2/neu Peptide GP2 + GMCSF Vaccine and Trastuzumab in Breast Cancer Patients • 17 patients treated with GP2 + GM-CSF + trastuzumab Conducted at Brooke Army Medical Center and Mary Crowley Medical Research Center • Phase I Safety Trial of the GP2 + GM-CSF Vaccine in Combination with the Helper Peptide AE37 + GM-CSF Vaccine • 14 patients treated with GP2 + AE37 + GM-CSF Protocol No. 04-20017 / IRBNet ID 20307 • Phase Ib Trial of HER2/neu Peptide (GP2) Vaccine in Breast Cancer Patients • 18 patients treated with GP2 + GM-CSF Commercial Opportunity for GP2 in Breast Cancer • 1 in 8 U.S. women (12.4%) will develop invasive breast cancer over her lifetime, with 266k new breast cancer patients per year in 2018 • GP2's target market is 6-30% of available breast cancer market or up to 2.4x that of Herceptin in adjuvant setting • GP2 could be a long term treatment that treats survivors (3.1m as of 2018) • Herceptin/Perjeta/Nerlynx/Kadcyla pricing from $75k - $125k per patient per year • 11 doses over 3 years in initial indication Herceptin GP2 US Market Potential (Size = 3.1m current breast cancer survivors and 266k new patients per year) HER2/neu Expressors (1-3+) 25% (3+) 25-75% (1-3+) HLA Type 100% 50-80% (2/3/24/26) Node Positive (NP) or High Risk Node Negative (HRNN) 50% 50% Target Market Potential 12.5% 6.25 - 30% Theoretical New Patients per Year 16,750 – 79,800 Adjuvant Patients Treated per Year (est. from sales) 27,000 – 40,000 Estimated Adjuvant Setting US Revenue ($ billions) $2-3 Estimated Price (first year) $74,500 TBD (6 primary + 1 booster) Estimated Price (booster) Not Approved TBD (4 boosters over 2 years) Estimated 2017 Global Revenue ($ billions) $7 Adjuvant Setting $2-3 Metastatic Breast Cancer $4-5 Multi $ Billion Revenue Potential Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates "Snehal Patel, CEO of Greenwich LifeSciences, commented, "While we are focused on the upcoming GP2 Phase III breast cancer clinical trial, and are also exploring how to expand the use of GP2 in additional indications through supplemental clinical trials, we have decided to explore the addition of new immunotherapy product candidates to our pipeline at both the pre-clinical and clinical stages of development. The objective of the coronavirus vaccine program is to leverage the development team's experience in achieving 100% protection against lethal levels of pneumonic plague infection to increase the percent protection and duration of protection of coronavirus vaccines under development. It is not clear how long one will be protected by the current Covid-19 vaccines and none that have been developed to date offer 100% protection. We are hopeful that our approach, which showed 100% protection against pneumonic plague, may lead to greater and longer lasting protection compared to existing Covid-19 vaccines under development."" https://investor.greenwichlifesciences.com/news-events/press-releases/detail/23/for-pre-clinical-coronavirus-vaccine-candidates Personally- is this a reason to buy GLSI? No. Is this a reason to hold GLSI? No. Is this bad news for GLSI? Absolutely not. This holds no impact in my position of GLSI. It is definitely bullish news. Estimated Revenue https://www.sec.gov/ix?doc=/Archives/edgar/data/1799788/000149315221007532/form10-k.htm Cash As of December 31st, 2020, In September 2020, the Company completed its initial public offering and raised $7,250,002 in gross proceeds and $6,207,502 in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. In December 2020, the Company completed a follow-on offering and raised $26,400,000 in gross proceeds and $23,959,000 in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. The Company met and exceeded those predictions thus mitigating any substantial doubt about the Company's ability to continue as a going concern as defined by ASU 2014-05 and its ability to satisfy the estimated liquidity needs for the twelve months from the issuance of the financial statements. As of December 31, 2020, the Company had cash of $28,660,375. https://www.sec.gov/ix?doc=/Archives/edgar/data/1799788/000149315221007532/form10-k.htm Balance Sheet FY20 Price Target General Consensus 1 Wall Street analysts have issued ratings and price targets for Greenwich LifeSciences in the last 12 months. Their average twelve-month price target is $75.00, predicting that the stock has a possible upside of 116.01%. The high price target for GLSI is $75.00 and the low price target for GLSI is $75.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy." - https://www.marketbeat.com/stocks/NASDAQ/GLSI/price-target/ There's never anything wrong with securing profits. A low risk strategy would be to secure profits on the run up by selling before the catalyst drops. One optimal approach is sell enough shares to cover your cost basis and let your remaining shares ride into the catalyst. Curiously, GLSI has waited until circa 1:20 pm est to run on multiple occasions- I can't even begin to speculate why but unless GLSI hits over $150 in the morning I will most likely be hanging out in the position until at least 2pm est. Obviously, I'll use TA to monitor the situation and will adjust my current strategy depending on new data. With such a low float, low volume stock, poised to release such great news, it makes a realistic price target very hard to chart out or even predict with any confidence. If $GLSI can break past resistance in the low 50s, it could easily gap back up over 100 with enough volume. The possibility is there, the likelihood is unknown. I will be watching GLSI closely on 04/09, and will use indicators to help navigate the best exit price. Note, on their topline data, RSI went well past 95, so if one sold at 70 there would have been a lot of money left on the table. Couple final tips to help you determine when to sell: Don't be greedy. No one ever went broke taking profits. If it's worth screenshotting, it's worth selling. Insider Trading From https://fintel.io/n/us/glsi we can see there were several insider purchases of the stock before the initial topline data was announced and have not see any selling of the stock, even during it's 3000% run. This makes me very bullish. Institutional Ownership Institutional Ownership (cont'd) All of the highlighted institutions opened positions for the first time in GLSI (17 out of 19). Institutional buy ins from major players like Vanguard, Blackrock, BAC, and Wells Fargo makes me extremely bullish. [link] [comments]  |
| U.S. Market Recap - Monday, April 5, 2021 Posted: 05 Apr 2021 01:33 PM PDT Dow +1.13%, S&P 500 +1.44%, Nasdaq +1.67%, Russell 2000 +0.49%
[link] [comments]  |
| Dow, S&P 500 rally to records, boosted by strong economic data Posted: 05 Apr 2021 12:40 PM PDT NEW YORK (Reuters) - U.S. stocks rallied on Monday, as a round of strong economic data on the labor market and services sector buoyed investor optimism for the economic reopening and a muted climb in the 10-year U.S. Treasury yield kept inflation worries at bay. An ISM survey for March showed a measure of U.S. services industry activity jumped to a record high. The data followed Friday's report showing U.S. nonfarm payrolls surged by 916,000 jobs in March, trouncing forecasts. Investors have bet on sectors poised to lead an economic reopening, such as energy, financials and materials. A climbing yield on the 10-year U.S. Treasury note has dented appetite for technology stocks. Despite strong economic data, gains were led by sectors that have underperformed recently, including communication services, consumer discretionary and tech, as the 10-year yield remained below a 14-month high hit last week. "One of the fears in March was that the rise in rates meant you need to take multiples down," said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management in Seattle. "It's not the reopening trade at this point, it is higher interest rates are here but not accelerating so the whole economy is being lifted." The Dow Jones Industrial Average rose 385.96 points, or 1.16%, to 33,539.17, the S&P 500 gained 59.11 points, or 1.47%, to 4,078.98 and the Nasdaq Composite added 234.78 points, or 1.74%, to 13,714.89. With speedy vaccinations and additional government stimulus helping the S&P 500 and the Dow clinch all-time highs, focus now turns to progress on a massive infrastructure plan and the upcoming corporate earnings season. The tech-heavy Nasdaq is still about 4% below its February high as the recent spike in bond yields spurred inflation concerns and made growth stocks less attractive. Energy shares were the worst performing sector, following a sharp drop in oil prices. Reopening plays gained, as the S&P 1500 airlines index jumped 3.43% after the U.S. Centers for Disease Control and Prevention said fully vaccinated people can safely travel at "low risk." The agency had held off for weeks on revising guidance that discouraged all non-essential trips. U.S. Treasury Secretary Janet Yellen said she was working with G20 countries to agree on a global corporate minimum tax rate to end a "30-year race to the bottom on corporate tax rates." [link] [comments]  |
| Stock Simulator Apps for kids? Posted: 05 Apr 2021 11:34 AM PDT Sorry if this has been asked before but I was wondering if there was some sort of stock simulator app for my kids to use. They are both 13 and I bought them a few shares each of RBLX. Ideally, I'd like something where they can input the number of shares they have at a given price so they can get real time numbers whenever they want to check. If anyone has any suggestions they are greatly appreciated. Thank you! [link] [comments]  |
| DraftKings Acquires BlueRibbon Posted: 05 Apr 2021 04:42 AM PDT DraftKings will now be able to enhance the customer experience by integrating BlueRibbon's unique jackpot functionality, including personalized promotions and rewards tailored to the individual customer or jackpots DraftKings will now be able to enhance the customer experience by integrating BlueRibbon's unique jackpot functionality, including personalized promotions and rewards tailored to the individual customer or jackpots that pay out across DraftKings' various product offerings. [link] [comments]  |
| Here is a Market Recap for today Monday, April 5, 2021 Posted: 05 Apr 2021 01:20 PM PDT PsychoMarket Recap - Monday, April 5, 2021 Stocks jumped on Monday, continuing their strong performance from last Friday, with the S&P 500 (SPY) and Dow Jones (DIA) recording fresh highs. The tech-heavy Nasdaq (QQQ) outperformed, closing the day 2% up. Market participants remain encouraged by President Biden's recent infrastructure proposal, a better-than-expect monthly job report, and are looking ahead to a week of commentary from Federal Open Market Committee (FOMC) members. The March Jobs Report blew past consensus estimates to record the fastest pace of job growth since last summer. Nonfarm payrolls increased by 916,000 for the month while the unemployment rate fell to 6% (unemployment rate was 14.6% in April 2020). Economists surveyed by Dow Jones had been looking for an increase of 675,000 and an unemployment rate of 6%. Quincy Krosby, chief market strategist at Prudential Financial said, "It [the jobs report] shows that the economy is healing, that those who lost their jobs are coming back into the workforce as the recovery continues and restrictions are lifted." President Biden's plan, called the American Jobs Plan, proposes to spend $2.25 trillion over 8 years to rehabilitate and build out the nation's transportation infrastructure, expand domestic manufacturing and workforce development, modernize the electrical grid, and fund the research, development, and implementation of clean energy technologies. See a full list of items from the bill here. Looking ahead, this week will be chock full of commentary from Federal Open Market Committee (FOMC) members, who will offer their assessment of the latest batch of economic data and how they will proceed. . Chicago Fed President Charles Evans, Richmond Fed President Thomas Barkin and St. Louis Fed President Jim Bullard are each slated to deliver public remarks later this week, and Fed Chair Jerome Powell will speak at an International Monetary Fund (IMF) panel regarding the global economy Thursday afternoon. In a note to client, Wells Fargo economist Sam Bullard said, " "While the consensus of the FOMC continues to suggest that the committee will wait for their forecasts to be realized before taking policy action, it will be interesting to see if there is any intense discussion about the implications of the stronger outlook, particularly around inflation. Most Fed officials expect any pick-up in inflation to be "transitory," yet we suspect there are a few officials that are pushing back on that narrative." Highlights
"Perseverance is not a long race; it is many short races one after the other." - Walter Elliot [link] [comments]  |
| Posted: 05 Apr 2021 12:24 PM PDT I'm bullish on Apple for the next few years. I was looking to buy a 130 strike leap for Jan 2023. It costs about $1900. At the moment that's about how much I have in Apple shares. Would it be unwise to sell the shares to buy the leap? At the moment selling the apple shares would be the only way I can afford the option. [link] [comments]  |
| Posted: 05 Apr 2021 12:53 PM PDT I'm acutely aware of the institutional moves that sent it down last week, but I'm curious: How much of the price movement is related to a change in the company's outlook? I know there's a good bit of bearish sentiment with all the changes going on in media, but I'm curious whether folks have an opinion on the overall outlook from here. Basically, my question is twofold. One, I'm curious, what the hell happened to send it tumbling like that? Two, where does the company go from here? I welcome insight on what happened and peoples' opinions on the company. [link] [comments]  |
| Best stocks for Biden's infrastructure plan Posted: 05 Apr 2021 02:43 AM PDT This is great article from Seeking Alpha but since it's against the rules to link SA articles here I'll just copy/paste. Engineering & Construction.Analyst Sean Eastman says "the reinforced focus on infrastructure stimulus and on climate resilience will be powerful multiyear themes."
Machinery & Equipment Rental.Analysts Steve Barger and Ken Newman see "particular upside potential for our construction machinery OEMs, equipment rental companies, and rail transportation manufacturers."
Metals.Analyst Phil Gibbs says the spending program will offer a demand catalyst in the "intermediate term," but the size of the package will likely be closer to $500B to $1T.
Diversified Industrial.Analyst Jeff Hammond thinks the entire group would benefit for fundamental and sentiment reasons.
Auto Suppliers.Analyst James Picariello says the plan is well targeted for the blueprints for mass EV adoption, which are "strict and consistent emissions regulations, generous consumer tax incentives, and a determinable charging infrastructure buildout."
Vertical Software.Analyst Jason Celino thinks the plan would "accelerate digitization opportunities across the architecture and construction industry."
Chemicals.Analyst Aleksey Yefremov highlights benefits for "industrial coatings, polyurethanes, epoxy, PVC, and chlor-alkali."
Communication Services.Analyst Brandon Nispel says the bill "is positive for infrastructure providers (tower operators) and neutral to negative for network providers (wireless carriers and cable operators)."
Entertainment and Video Games.Analyst Tyler Parker says the plan for bringing high-speed broadband to every American will help domestic online vide games
Semiconductors.Analysts John Vinh and Wes Twigg say "expansion incentives would likely be a tailwind for semiconductor equipment demand while easing the capex burden on manufacturers."
Utilities.Analyst Sophie Karp notes the majority of the impact on the sector would not come from direct spending, but from fiscal incentives.
Oil and Gas Exploration and Production.Analyst Leo Mariani says the plan "is likely to have a bit of a long-term negative for traditional U.S. oil E&Ps if it accelerates the transition away from fossil fuels for transportation purposes, but we generally think that other variables that normally impact the price of oil over the next few years are much more likely to affect energy stocks as opposed to the impacts of this bill, which will take a healthy part of this decade and into the next to make a material impact." Life Science Tools.Analyst Paul Knight says "a specific call-out of 'biotechnology' as a key technology investment is positive." [link] [comments]  |
| I just made my first call option trade. Posted: 05 Apr 2021 01:01 PM PDT I bought a SGU 4/16 $10 call at .80 and sold it for 1.05. This was my first call option trade. I fear I may have sold too early, but I am happy to have made a profit. Did I make the right choice selling when I did? [link] [comments]  |
| Heron Therapeutics [HRTX] biotech // Posted: 05 Apr 2021 11:48 AM PDT Has anyone been in on this ticker? I was doing some research to jump into the Biotech sector and noticed this seems like a good time to get in such low cost. However, I am nervous since it IPO was at like $500. I've tried to do some research and haven't been able to come up with too much to help my decision to get in or not. Any positive feedback, DD, insight to share -why you're in and like it -or why you don't like it -and why the F did the drop like 90% since IPO Thanks 🙏 [link] [comments]  |
| Is The U.S. Finally Embracing Tidal Energy? Posted: 05 Apr 2021 10:42 AM PDT SOURCE: https://oilprice.com/Energy/Energy-General/Is-The-US-Finally-Embracing-Tidal-Energy.html By Tsvetana Paraskova - Apr 05, 2021, 12:00 PM CDT The United States has made the first step toward harnessing the potential of wave energy, a powerful source of renewable energy which researchers have been studying for decades. The Federal Energy Regulatory Commission (FERC) issued last month a license for what would be the first commercial-scale, utility grid-connected wave energy test site in the United States. Oregon State University received that license to build and operate the PacWave South testing facility as the industry is developing technology and devices potentially capable of harnessing the power of ocean waves. Despite decades of studies, wave energy is still little developed—both in the U.S. and elsewhere—because researchers are still looking at ways to reconcile feasibility and costs in a complex marine environment. In theory, the potential is enormous. In practice, wave energy will need a lot more testing and technology development if it hopes to become a viable renewable energy source. Nevertheless, a testing facility operational by the middle of this decade could give the impetus the U.S. industry needs to test various technologies for generating electricity from waves and attract investors in the most promising technology. The Biden Administration's support of renewable energy could also help with industry innovation. The U.S. is one of the best places in the world for ocean wave energy generation, according to the Energy Information Administration (EIA). Ocean waves have tremendous energy, and the theoretical annual energy potential of waves off the coasts of the United States is estimated to be as much as 2.64 trillion kilowatt hours (kWh). This equals around 64 percent of U.S. electricity generation in 2019, the EIA says.Related: U.S. Oil Production Is About To Climb The potential is there, and it is tremendous. Still, the industry now needs to test and possibly show that wave energy can make a difference with viable solutions in the drive for boosting renewable energy generation. Oregon State University's project leaders hope to obtain from FERC construction authorization for the PacWave South testing facility later this spring. Current timelines suggest that construction could begin this summer, and the facility could be operational by 2023, OSU says. "We know there is still work to do to make this project a reality, but this is a huge moment for this project and for the industry as a whole," Burke Hales, chief scientist for PacWave, said in a statement. The World Energy Council estimates that 10 percent of the worldwide electricity demand could be met by harvesting ocean energy, OSU said. The PacWave test facility could be the companies' place to showcase technology in order to attract investors in their proposed developments, according to Hales. "Even somebody like Bill Gates isn't going to pay somebody millions of dollars to do tests that they think will fail," Hales told Grist's Ysabelle Kempe. Innovation and testing of devices could unlock the tremendous energy potential of ocean waves, which is highest along the Pacific shorelines: California, Oregon, Washington, Alaska, and Hawaii, according to a recent study of the National Renewable Energy Laboratory funded by the Department of Energy. The study focuses on the technical resource—the proportion of the theoretical resource that can be captured using existing technology options. The study found that utilizing just one-tenth of the technically available marine energy resources in the 50 states would equate to 5.7 percent of the current U.S. electricity generation, or enough energy to power 22 million homes. DOE's Pacific Northwest National Laboratory has identified "energy hotspots" of wave power along the Washington, Oregon, and California coasts. "Wave power is a significant, sizeable resource," marine coastal science advisor Simon Geerlofs says. Yet, he noted that wave energy still has challenges to overcome, including big hurdles like ensuring durability and efficiency of wave energy converters and cost-competitiveness with other energy resources. [link] [comments]  |
| TDOC: Polarizing Analyst Ratings Posted: 05 Apr 2021 09:04 AM PDT I noticed that the Equity Summary Score for TDOC was further downgraded to very bearish today. I researched to see how others were rating TDOC. Some are giving majority of buy signals while others are giving majority of sell signals. Why is it so polarizing? I understand that it's a prediction but Just trying to understand why there are such big discrepancies. [link] [comments]  |
| Parking some money in EPD for a year for the dividend? Good idea? Posted: 05 Apr 2021 01:32 PM PDT Hi everyone, was thinking of parking about 10k in EPD for a year or two to collect the $1.80 dividend currently trading around $22. Seems like a relatively stable stock with stable dividend to me. Is this a terrible idea or decent? Thanks in advance. [link] [comments]  |
| Posted: 05 Apr 2021 06:37 AM PDT
NNOX opened up 50% pre-market. [link] [comments]  |
| Resources to learn about ad tech business Posted: 05 Apr 2021 12:38 PM PDT I was looking to buy pubmatic when it IPO'ed in december. I didn't and it's stock doubled. I am not regretting because I didn't fully understand the business at that time. It would have been a purchase without DD and I would have easily lost money too. I am seeing lot of ad tech stocks doing well. Can some one point me to resources to systematically understand this business? I see google analytics, segment, mix panel etc. The n I see Trade Desk, PubMatic. I am curious how they all play together and which company does what. Also I read somewhere that ROKU is building an advertising moat. I am confused on how all of these work. [link] [comments]  |
| Can someone help me understand how the Coca Cola Company is set up? Posted: 05 Apr 2021 07:36 AM PDT To clarify I don't mean the fundamental process of bottling cola but the way the company is set up. I'm fairly new to investing and trying to do some DD as Coca Cola seems undervalued to me, but it looks like they have several different companies and tickers and I'm not sure which one is the main parent company whose results I should be looking at. Looking on Yahoo finance they have the tickets $KO (Which I assume is the parent?), $CCH.L, $COKE and $CCEP (Which I assume is their European arm?). Which company should I be looking at if I want to see how the overall global business is performing? Thanks in advance and sorry if this isn't the right place to post! [link] [comments]  |
| Reasons to be Bullish about Novavax (NVAX) Posted: 05 Apr 2021 08:16 AM PDT I have been following NVAX for a while and think that it will be the big winner at the end of all this COVID stuff. I found an excellent writeup/summary which touched all the important points and thought it would be useful here, which I'll summarize below. Novavax's vaccine is crazy effective, cheap to make, and easy to transport. "The way Novavax' vaccine works is different even from the ones previously mentioned and approved for use in the United States. NVX-CoV2373 (the formal name for their vaccine) is a protein-based subunit vaccine candidate engineered from the genetic sequence of SARS-CoV-2. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigens derived from the coronavirus spike (S) protein. It is adjuvanted 4 with Novavax' patented saponin-based Matrix-MTM which enhances the immune response and stimulates high levels of neutralizing antibodies. This vaccine candidate does require two doses, spaced three weeks apart. " " Second-generation vaccines, of which Novavax is one, are identified based on their potential to provide protection with a single dose, exhibit stability in greater temperature ranges, remain stable throughout the manufacturing process, yield an improved or differentiated immune response, and use a diverse range of antigens. They are historically cheaper and have had higher levels of efficacy and safety. " They already have over a 200 million orders and they have a worldwide supply chain and distribution already set up. "To date, Novavax has increased its projected global manufacturing production rate of NVX-CoV2373 to be over two billion annualized doses when they're at full capacity, which is expected to occur in mid-2021. Of this anticipated capacity, approximately one billion doses will be manufactured by the Serum Institute of India Private Limited (SIIPL). Novavax has developed partnerships with entities across the globe to increase its manufacturing capacity and vaccine supplies " "Novavax has entered into advanced purchase agreements with various countries globally that, if the vaccine is approved, are expected to result in the delivery of approximately 200 million doses of NVX-CoV2373 throughout 2021 and into the first half of 2022 " It looks like coronavirus is not going away, so people will continue to need boosters and shots to take care of the variant strains. "From what I've learned about Novavax, they seem to be well-positioned to give COVID-19 the knockout punch. Their underlying recombinant nanoparticle technology has the ability to accurately target viral pathogens and create protein antigens organized around a polysorbate-based nanoparticle core, the assembly of which resembles the native presentation of the pathogen being targeted. This process creates highly-immunogenic, long-lasting, yet safe, vaccines that can tackle not only COVID-19 and its variant strains, but also a wide variety of other disease organisms. One of Novavax' near-term clinical development work is evaluating the viability of certain combination vaccines, which, if successful, could potentially lead to a seasonal 3-in-1 or 2-in-1 vaccine shot that would take care of influenza, COVID-19, and RSV " TLDR: Honestly, no company has the combination of (1) 90%+ efficacy, (2) easy transport and storage, and (3) easy modification like Novavax does. I think this vaccine, along with Pfizer/BioNTech (which I owned last year) will end up the big winner from all this. Moderna is behind Pfizer, AstraZeneca is an absolute mess (the clots appear to be real), and Johnson & Johnson is simply not all that effective. Price targets on eTrade on average are $323, that's 74% upside. Catalysts coming in April (UK) and May (US). Obviously, all vaccine plays carry risk, but there's no logical reason for the recent downward pressure on NVAX's price. It's part of my well-diversified portfolio. Position: 50 shares. [link] [comments]  |
| What are the alternatives to VOO and VTI for european investors? Posted: 05 Apr 2021 10:12 AM PDT I have seen a lot of advice to invest saving into on of the two mentioned above for long term saving. Unfortunately, I am from Germany and don't have access to these ETF. Right now I have Core MSCI World, Global Clean Energy and NASDAQ100 as stock variation. Can you recommend any other ETFs to invest in similar to VTI/VOO or are the two choose by me fine? [link] [comments]  |
| My attempt at a 50K portfolio allocation Posted: 05 Apr 2021 08:59 AM PDT I've been a day-trader and option market trader for approximately 7 years. Honestly my previous year record as a swing/day trader was very poor, and so I educated myself about trading options and spreads in particular. This year alone I've done almost $40K in profit, and I've enhanced my technical, fundamental and macro analysis to make decisions on whether to go long/short etc and then initiated vertical spreads from there. (30-45 DTE) Having said that, I'm thinking about finally creating my own portfolio. I've never done this, despite having a finance background. My goals are quite simple: 1) Set a sector weight cap limit for each sector, so that if there's a breach, I sell some stock and bring it down. Also setting a "stock" weight limit, etc. So I'll be watching those carefully and then I'll know when to take profits or rebalance my positions. This is just a sample portfolio, and I'm going to do more research on the names... But I'm just wondering is 16 stocks too much for $50K? Should I increase the Value per stock to $5K instead of $2.5K? Ideally, I'd like to generate a dividend yield of near 3-4% per year, while getting between 5-10% per year on my portfolio. Again, I have to assess my portfolio for these characteristics, but for now that's the plan. Q1) What are your thoughts on my portfolio structure so far? Q2) Should I decrease my sample size? What would you recommend if so. Q3) What are your thoughts on the sector allocation? Too many sectors? Also feel free to recommend some stocks in the sectors that you're familiar with, and any other advice. I'm honestly doing very well with the Spreads and I want to continue doing it, but I'm also aware that I could return to my old losing habits. [link] [comments]  |
| You are subscribed to email updates from Stocks - Investing and trading for all. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
No comments:
Post a Comment